Key stats
About Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF
Home page
Inception date
Oct 4, 2021
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Capitalizes
Income tax type
Capital Gains
Primary advisor
Fubon Asset Management Co., Ltd.
ISIN
TW0000089705
Fubon NYSE FactSet Global Genomics and Immuno Biopharma Exchange Traded Fund seeks investment results that closely track the performance of NYSE FactSet Global Genomics and Immuno Biopharma Index, before fees and expenses
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.59%
Health Technology97.60%
Health Services0.92%
Bonds, Cash & Other1.41%
Futures1.48%
Cash−0.07%
Stock breakdown by region
North America62.07%
Europe31.64%
Asia6.28%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
00897 invests in stocks. The fund's major sectors are Health Technology, with 97.66% stocks, and Health Services, with 0.92% of the basket. The assets are mostly located in the North America region.
00897 top holdings are Genmab A/S and BeOne Medicines Ltd., occupying 5.12% and 5.01% of the portfolio correspondingly.
00897 assets under management is 1.43 B TWD. It's risen 1.31% over the last month.
00897 fund flows account for −167.06 M TWD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, 00897 doesn't pay dividends to its holders.
00897 shares are issued by Fubon Financial Holding Co., Ltd. under the brand Fubon. The ETF was launched on Oct 4, 2021, and its management style is Passive.
00897 expense ratio is 1.05% meaning you'd have to pay 1.05% of your investment to help manage the fund.
00897 follows the NYSE FactSet Global Genomics and Immuno Biopharma Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
00897 invests in stocks.
00897 price has risen by 0.56% over the last month, and its yearly performance shows a −11.61% decrease. See more dynamics on 00897 price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −2.03% over the last month, showed a 13.12% increase in three-month performance and has decreased by −12.56% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −2.03% over the last month, showed a 13.12% increase in three-month performance and has decreased by −12.56% in a year.
00897 trades at a premium (1.93%) meaning the ETF is trading at a higher price than the calculated NAV.